Internal Medicine - Division of Hematology, Ohio State University Comprehensive Cancer Centre, Columbus, OH, USA.
BMJ. 2022 Apr 20;377:e063439. doi: 10.1136/bmj-2020-063439.
The improved understanding of lymphoma biology and recent advances in the field of cancer immunology have paved the way for the development of many effective small molecule inhibitors and immunotherapies in B cell non-Hodgkin's lymphomas. This article reviews novel treatments that have been approved recently by the US Food and Drug Administration and are now routinely used in clinical practice. It discusses their mechanisms of action, efficacy and safety, current therapeutic roles, and future directions in the treatment paradigm of different types of B cell non-Hodgkin's lymphoma. It also reviews other exciting novel treatments that are not yet approved but have unique mechanisms of action and have shown encouraging early results.
对淋巴瘤生物学的认识不断提高，以及癌症免疫学领域的最新进展，为 B 细胞非霍奇金淋巴瘤的许多有效小分子抑制剂和免疫疗法的发展铺平了道路。本文综述了最近获得美国食品和药物管理局批准并已在临床实践中常规使用的新型治疗方法。讨论了它们的作用机制、疗效和安全性、当前的治疗作用以及不同类型 B 细胞非霍奇金淋巴瘤治疗模式的未来方向。还回顾了其他尚未获得批准但具有独特作用机制并显示出令人鼓舞的早期结果的令人兴奋的新型治疗方法。
